This trial is testing a new approach to treating opioid use disorder - a vaccine targeted against oxycodone. The goal is to develop a vaccine against oxycodone and heroin. The study will test safety, antibody production, and efficacy.
2 Primary · 0 Secondary · Reporting Duration: Throughout the testing session [i.e., pre-dose baseline (Time 0)- Thru- 4.5 hours post-dose].
Experimental Treatment
Non-Treatment Group
45 Total Participants · 3 Treatment Groups
Primary Treatment: OXY 100 mg · Has Placebo Group · Phase 1 & 2
Participation is compensated
You will be compensated for participating in this trial.
Age 18 - 59 · All Participants · 8 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: